Abstract
The optimal end point for phase II studies for recurrent glioblastoma (GBM) is unclear and a matter of debate. Moreover, data about post-progression survival (PPS) after the first disease progression in GBM patients treated according to EORTC 26981/22981/NCIC CE.3 trial are limited. The aim of this study was to evaluate the PPS in GBM patients. The analysis was made with a database on 1,006 GBM patients followed prospectively between 06/2005 and 06/2010. Eligibility criteria for the study were: age ≥18 years; PS: 0–2; chemotherapy given at disease progression after RT/TMZ. 232 patients (mean age 52 years, range 18–77 years) were enrolled. The median PFS following second line chemotherapy (PFS2) was 2.5 months (95 % CI 2.1–2.9) and the rate of patients free of progression at 6 months (PFS2-6 mo), was 21.6 % (95 % CI 16.3–26.9 %). The median PPS was 8.6 months (95 % CI 7.4–9.8), PPS rates were: PPS-6: 66 % (95 % CI 60.3–72.9 %), PPS-9: 48.2 % (95 % CI 41.5–54.9 %) and PPS-12: 31.7 % (95 % CI 25.2–38.2 %). PPS in unselected patients treated with alkylating agents is about 8 months. PPS rates could be of interest as an end point in future studies in recurrent GBM.
Original language | English |
---|---|
Pages (from-to) | 399-404 |
Number of pages | 6 |
Journal | Journal of Neuro-Oncology |
Volume | 121 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2014 |
Keywords
- End points
- Glioblastoma
- Post-progression survival
- Progression-free survival
- Recurrence
ASJC Scopus subject areas
- Clinical Neurology
- Cancer Research
- Oncology
- Neurology
- Medicine(all)